Intuitive Surgical, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Intuitive Surgical, Inc. stock analysis ISRG overview
Somewhat Bullish +50

Goldman Sachs Maintains Buy Rating on Intuitive Surgical (ISRG)

📉 Goldman Sachs lowered its price target on Intuitive Surgical (ISRG) to $558 from $621 while maintaining a Buy rating.

⚠️ The firm cited MedTech as being in one of its weakest periods in 15-20 years regarding performance, valuation, and outlook.

📉 Bank of America also lowered its price target on ISRG to $520 from $650 but kept a Buy rating after hosting 34 medtech companies.

🤖 BofA highlighted concerns about "data centers over healthcare" and noted fewer product cycles in the current year.

💰 Intuitive Surgical reported Q1 adjusted EPS of $2.50, beating the consensus estimate of $2.11.

📈 Revenue for the quarter totaled $2.77 billion, surpassing the consensus estimate of $2.62 billion.

🔬 Worldwide procedures across da Vinci and Ion systems grew approximately 17% year-over-year.

🤖 da Vinci procedures increased by about 16%, while Ion procedures saw a significant jump of approximately 39%.

🏥 The company placed 431 da Vinci surgical systems, up from 367 in the first quarter of 2025.

🔌 Placement of Ion endoluminal systems reached 52 units compared to 49 last year.

🏢 Intuitive Surgical develops and markets products supporting minimally invasive care in the US and internationally.

⚖️ Analysts note pressure from sector rotation, slower growth, reimbursement issues, competitive risks, and aging investment narratives.

📉 Inflation pressure post-war and ACA utilization worries are contributing to the challenging medtech valuation environment.

Bullish Signals
  • Goldman Sachs maintained a Buy rating on Intuitive Surgical (ISRG), signaling continued institutional confidence despite sector headwinds.
  • Intuitive Surgical reported Q1 adjusted EPS of $2.50, which significantly beat the consensus estimate of $2.11.
  • Revenue totaled $2.77B in the quarter, surpassing analyst expectations of $2.62B.
  • Worldwide procedures across da Vinci and Ion grew approximately 17% year-over-year, demonstrating strong operational momentum.
  • da Vinci procedures increased by approximately 16%, while Ion procedures saw robust growth of approximately 39%.
  • The company placed 431 da Vinci surgical systems in the quarter, a notable increase from 367 units placed in the first quarter of 2025.
  • Ion endoluminal system placements reached 52 units, up from 49 last year, indicating expanding market penetration.
Risk Factors
  • Goldman Sachs lowered its price target on Intuitive Surgical from $621 to $558, citing that the MedTech sector is experiencing one of its weakest periods in 15-20 years due to valuation pressures and slower growth.
  • Bank of America reduced its price target from $650 to $520, highlighting concerns over fewer product cycles, ACA and utilization worries, post-war inflation pressure, and a shift in capital flows toward data centers rather than healthcare.
  • Analysts explicitly cited competitive risks and reimbursement issues as key factors contributing to the sector's weak performance and negative outlook revisions.
Full Analysis
Goldman Sachs maintained its Buy rating on Intuitive Surgical (ISRG) but lowered its price target from $621 to $558 as of May 27, 2026. The firm noted that the MedTech sector is experiencing one of its weakest periods in 15-20 years due to performance and valuation pressures, slower growth, reimbursement issues, competitive risks, and aging investment narratives. This adjustment follows a similar move by Bank of America on May 18, 2026, which reduced its price target from $650 to $520 while maintaining a Buy rating, citing a "new reality of medtech valuations" driven by fewer product cycles, ACA and utilization concerns, post-war inflation, and shifting capital flows toward data centers. Despite the analyst downgrades, Intuitive Surgical reported strong financial results for the first quarter with adjusted EPS of $2.50, beating the consensus estimate of $2.11, and revenue of $2.77 billion, surpassing the expected $2.62 billion. Worldwide procedures grew approximately 17% year-over-year, with da Vinci surgical systems placements rising to 431 from 367 in the first quarter of 2025, and Ion endoluminal system placements increasing to 52 from 49 the previous year. The company continues to develop and market products supporting minimally invasive care globally.